Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer
dc.contributor.author | Bulumulle, Anushi | |
dc.contributor.author | Brody, Heather | |
dc.contributor.author | Macherla, Shravanti | |
dc.contributor.author | Walker, Paul R. | |
dc.contributor.author | Sehgal, Kartik | |
dc.contributor.author | Gill, Ritu R. | |
dc.contributor.author | Qilleri, Aleksandra | |
dc.contributor.author | McDonald, Danielle C. | |
dc.contributor.author | Cherry, Cynthia R. | |
dc.contributor.author | Shea, Meghan | |
dc.contributor.author | Huberman, Mark S. | |
dc.contributor.author | VanderLaan, Paul A. | |
dc.contributor.author | Weiss, Glen J. | |
dc.contributor.author | Costa, Daniel B. | |
dc.contributor.author | Rangachari, Deepa | |
dc.date.accessioned | 2022-09-26T18:01:38Z | |
dc.date.available | 2022-09-26T18:01:38Z | |
dc.date.issued | 2021 | |
dc.identifier.doi | 10.1016/j.cllc.2020.05.028 | |
dc.identifier.issn | 1525-7304 | |
dc.identifier.uri | http://hdl.handle.net/10342/11327 | |
dc.language.iso | en_US | en_US |
dc.subject | Extended-interval dosing | en_US |
dc.subject | Immune-related adverse event | en_US |
dc.subject | Patient-physician preference | en_US |
dc.title | Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer | en_US |
dc.type | Article | en_US |
ecu.journal.issue | 3 | en_US |
ecu.journal.name | Clinical Lung Cancer | en_US |
ecu.journal.pages | e379-e389 | en_US |
ecu.journal.volume | 22 | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- BulumulleAssociationofExtendedDosingIntervalsorDelaysinPembrolizumabbasedRegimens.pdf
- Size:
- 884.2 KB
- Format:
- Adobe Portable Document Format
- Description: